Brief: Fusion Pharmaceuticals Reports Progress, Provides Corporate Highlights
06/01/2023 12:53
Jan 6 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS REPORTS PROGRESS AND PROVIDES
RECENT
CORPORATE HIGHLIGHTS
* FUSION PHARMACEUTICALS INC - FPI-2068 IND EXPECTED TO BE
SUBMITTED IN Q1 OF 2023
* FUSION PHARMACEUTICALS INC - FPI-1434 PHASE 1 DATA
EXPECTED IN
Q2 OF 2023
* FUSION PHARMACEUTICALS INC - FPI-1966 PHASE 1 STUDY OPEN
AND
ENROLLING PATIENTS; COMPANY EXPECTS TO PROVIDE CLINICAL DATA
UPDATE IN 2024
Source text for Eikon: ID:nCNW21Knba
Further company coverage: FUSN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary